Publication: A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand
Issued Date
2000-12-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-0034574496
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.31, No.4 (2000), 801-807
Suggested Citation
Srivicha Krudsood, U. Silachamroon, P. Wilairatana, P. Singhasivanon, W. Phumratanaprapin, K. Chalermrut, N. Phophak, C. Popa A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.31, No.4 (2000), 801-807. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26069
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand
Other Contributor(s)
Abstract
Recently, a combination of artesunate and mefloquine has proved effective, although is contraindicated in early pregnancy and young children. Azithromycin, a widely used antibiotic and has antimalarial effects, replace mefloquine as a new alternative antimalarial regimen. Two hundred and two uncomplicated falciparum malaria patients were randomly assigned to 1 of 3 regimens. Patients in group I (n = 68) received artesunate 200 mg once daily for 3 days, group II (n = 67) received artesunate 200 mg together with mefloquine 10 mg/kg on the first 2 days and artesunate 200 mg together with mefloquine 5 mg/kg on the third day, and group III (n = 67) received artesunate 200 mg together with azithromycin 50 mg once daily for 3 days. The 28 day cure rates were 44, 98 and 56%, respectively. The median time to recrudescence was significantly longer in group III. In conclusion, a combination of artesunate and azithromycin might be useful in treating children in whom bacterial and malarial infections may be concomitant. However, further work is required in order to enhance its clinical efficacy.